BACKGROUND: Other than several rare, highly penetrant familial syndromes, genetic risk factors for sporadic pancreatic cancer are largely unknown. ABO blood type is an inherited characteristic that in previous small studies has been associated with the risk of gastrointestinal malignancies. METHODS: We separately examined the relationship between ABO blood type and the risk of incident pancreatic cancer in two large, independent, prospective cohort studies (the Nurses' Health Study and Health Professionals Follow-up Study) that collected blood group data on 107 503 US health professionals. Hazard ratios for pancreatic cancer by ABO blood type were calculated using Cox proportional hazards models with adjustment for other known risk factors, including age, tobacco use, body mass index, physical activity, and history of diabetes mellitus. All statistical tests were two-sided. RESULTS: During 927 995 person-years of follow-up, 316 participants developed pancreatic cancer. ABO blood type was associated with the risk of developing pancreatic cancer (P = .004; log-rank test). Compared with participants with blood group O, those with blood groups A, AB, or B were more likely to develop pancreatic cancer (adjusted hazard ratios for incident pancreatic cancer were 1.32 [95% confidence interval {CI} = 1.02 to 1.72], 1.51 [95% CI = 1.02 to 2.23], and 1.72 [95% CI = 1.25 to 2.38], respectively). The association between blood type and pancreatic cancer risk was nearly identical in the two cohorts (P(interaction) = .97). Overall, 17% of the pancreatic cancer cases were attributable to inheriting a non-O blood group (blood group A, B, or AB). The age-adjusted incidence rates for pancreatic cancer per 100 000 person-years were 27 (95% CI = 23 to 33) for participants with blood type O, 36 (95% CI = 26 to 50) for those with blood type A, 41 (95% CI = 31 to 56) for those with blood type AB, and 46 (95% CI = 32 to 68) for those with blood type B. CONCLUSIONS: In two large, independent populations, ABO blood type was statistically significantly associated with the risk of pancreatic cancer. Further studies are necessary to define the mechanisms by which ABO blood type or closely linked genetic variants may influence pancreatic cancer risk.
BACKGROUND: Other than several rare, highly penetrant familial syndromes, genetic risk factors for sporadic pancreatic cancer are largely unknown. ABO blood type is an inherited characteristic that in previous small studies has been associated with the risk of gastrointestinal malignancies. METHODS: We separately examined the relationship between ABO blood type and the risk of incident pancreatic cancer in two large, independent, prospective cohort studies (the Nurses' Health Study and Health Professionals Follow-up Study) that collected blood group data on 107 503 US health professionals. Hazard ratios for pancreatic cancer by ABO blood type were calculated using Cox proportional hazards models with adjustment for other known risk factors, including age, tobacco use, body mass index, physical activity, and history of diabetes mellitus. All statistical tests were two-sided. RESULTS: During 927 995 person-years of follow-up, 316 participants developed pancreatic cancer. ABO blood type was associated with the risk of developing pancreatic cancer (P = .004; log-rank test). Compared with participants with blood group O, those with blood groups A, AB, or B were more likely to develop pancreatic cancer (adjusted hazard ratios for incident pancreatic cancer were 1.32 [95% confidence interval {CI} = 1.02 to 1.72], 1.51 [95% CI = 1.02 to 2.23], and 1.72 [95% CI = 1.25 to 2.38], respectively). The association between blood type and pancreatic cancer risk was nearly identical in the two cohorts (P(interaction) = .97). Overall, 17% of the pancreatic cancer cases were attributable to inheriting a non-O blood group (blood group A, B, or AB). The age-adjusted incidence rates for pancreatic cancer per 100 000 person-years were 27 (95% CI = 23 to 33) for participants with blood type O, 36 (95% CI = 26 to 50) for those with blood type A, 41 (95% CI = 31 to 56) for those with blood type AB, and 46 (95% CI = 32 to 68) for those with blood type B. CONCLUSIONS: In two large, independent populations, ABO blood type was statistically significantly associated with the risk of pancreatic cancer. Further studies are necessary to define the mechanisms by which ABO blood type or closely linked genetic variants may influence pancreatic cancer risk.
Authors: M Schenk; A G Schwartz; E O'Neal; M Kinnard; J K Greenson; J P Fryzek; G S Ying; D H Garabrant Journal: J Natl Cancer Inst Date: 2001-04-18 Impact factor: 13.506
Authors: S Zhang; H S Zhang; C Cordon-Cardo; V E Reuter; A K Singhal; K O Lloyd; P O Livingston Journal: Int J Cancer Date: 1997-09-26 Impact factor: 7.396
Authors: Guillaume Paré; Daniel I Chasman; Mark Kellogg; Robert Y L Zee; Nader Rifai; Sunita Badola; Joseph P Miletich; Paul M Ridker Journal: PLoS Genet Date: 2008-07-04 Impact factor: 5.917
Authors: David Melzer; John R B Perry; Dena Hernandez; Anna-Maria Corsi; Kara Stevens; Ian Rafferty; Fulvio Lauretani; Anna Murray; J Raphael Gibbs; Giuseppe Paolisso; Sajjad Rafiq; Javier Simon-Sanchez; Hana Lango; Sonja Scholz; Michael N Weedon; Sampath Arepalli; Neil Rice; Nicole Washecka; Alison Hurst; Angela Britton; William Henley; Joyce van de Leemput; Rongling Li; Anne B Newman; Greg Tranah; Tamara Harris; Vijay Panicker; Colin Dayan; Amanda Bennett; Mark I McCarthy; Aimo Ruokonen; Marjo-Riitta Jarvelin; Jack Guralnik; Stefania Bandinelli; Timothy M Frayling; Andrew Singleton; Luigi Ferrucci Journal: PLoS Genet Date: 2008-05-09 Impact factor: 5.917
Authors: Margaret A Gates; Mousheng Xu; Wendy Y Chen; Peter Kraft; Susan E Hankinson; Brian M Wolpin Journal: Int J Cancer Date: 2012-02-10 Impact factor: 7.396
Authors: Brian M Wolpin; Peter Kraft; Mousheng Xu; Emily Steplowski; Martin L Olsson; Alan A Arslan; H Bas Bueno-de-Mesquita; Myron Gross; Kathy Helzlsouer; Eric J Jacobs; Andrea LaCroix; Gloria Petersen; Rachael Z Stolzenberg-Solomon; Wei Zheng; Demetrius Albanes; Naomi E Allen; Laufey Amundadottir; Melissa A Austin; Marie-Christine Boutron-Ruault; Julie E Buring; Federico Canzian; Stephen J Chanock; J Michael Gaziano; Edward L Giovannucci; Göran Hallmans; Susan E Hankinson; Robert N Hoover; David J Hunter; Amy Hutchinson; Kevin B Jacobs; Charles Kooperberg; Julie B Mendelsohn; Dominique S Michaud; Kim Overvad; Alpa V Patel; Maria-José Sanchéz; Leah Sansbury; Xiao-Ou Shu; Nadia Slimani; Geoffrey S Tobias; Dimitrios Trichopoulos; Paolo Vineis; Kala Visvanathan; Jarmo Virtamo; Jean Wactawski-Wende; Joanne Watters; Kai Yu; Anne Zeleniuch-Jacquotte; Patricia Hartge; Charles S Fuchs Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-10-22 Impact factor: 4.254
Authors: Allison B Weisbrod; Naris Nilubol; Lee S Weinstein; William F Simonds; Steven K Libutti; Robert T Jensen; Stephen J Marx; Electron Kebebew Journal: J Clin Endocrinol Metab Date: 2012-10-23 Impact factor: 5.958
Authors: Charles C Chung; Wagner C S Magalhaes; Jesus Gonzalez-Bosquet; Stephen J Chanock Journal: Carcinogenesis Date: 2009-11-11 Impact factor: 4.944